» Articles » PMID: 28921763

Implementation and Preliminary Clinical Outcomes of a Pharmacist-managed Venous Thromboembolism Clinic for Patients Treated With Rivaroxaban Post Emergency Department Discharge

Overview
Journal Acad Emerg Med
Publisher Wiley
Specialty Emergency Medicine
Date 2017 Sep 19
PMID 28921763
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective was to describe the implementation, work flow, and differences in outcomes between a pharmacist-managed clinic for the outpatient treatment of venous thromboembolism (VTE) using a non-vitamin K oral anticoagulant versus care by a primary care provider (PCP).

Methods: Patients in the studied health system that are diagnosed with low-risk VTE in the emergency department are often discharged without hospital admission. These patients are treated with a non-vitamin K oral anticoagulant and follow-up either in a pharmacist-managed VTE clinic or with their PCP. Pharmacists in the VTE clinic work independently under a collaborative practice agreement (CPA). An evaluation of 34 patients, 17 in each treatment arm, was conducted to compare the differences in treatment-related outcomes of rivaroxaban when managed by a pharmacist versus a PCP.

Results: The primary endpoint was a 6-month composite of anticoagulation treatment-related complications that included a diagnosis of major bleeding, recurrent thromboembolism, or fatality due to either major bleeding or recurrent thromboembolism. Secondary endpoints included number of hospitalizations, adverse events, and medication adherence. There was no difference in the primary endpoint between groups with one occurrence of the composite endpoint in each treatment arm (p = 1.000), both of which were recurrent thromboembolic events. Medication adherence assessment was formally performed in eight patients in the pharmacist group versus no patients in the control group. No differences were seen among other secondary endpoints.

Conclusions: The pharmacist-managed clinic is a novel expansion of clinical pharmacy services that treats patients with low-risk VTEs with rivaroxaban in the outpatient setting. The evaluation of outcomes provides support that pharmacist-managed care utilizing standardized protocols under a CPA may be as safe as care by a PCP.

Citing Articles

JTH in Clinic: management of low-risk pulmonary embolism.

Han H, OHare C, Joyce E, Kline J, Greineder C, Barnes G J Thromb Haemost. 2024; 22(12):3406-3414.

PMID: 39395541 PMC: 11647568. DOI: 10.1016/j.jtha.2024.09.019.


The effect of pharmacist-led interventions on the appropriateness and clinical outcomes of anticoagulant therapy: a systematic review and meta-analysis.

Kefale B, Peterson G, Mirkazemi C, Bezabhe W Eur Heart J Qual Care Clin Outcomes. 2024; 10(6):488-506.

PMID: 39003246 PMC: 11873792. DOI: 10.1093/ehjqcco/qcae045.


Effect of pharmacist care on clinical outcomes and therapy optimization in perioperative settings: A systematic review.

Naseralallah L, Koraysh S, Alasmar M, Aboujabal B Am J Health Syst Pharm. 2024; 82(1):44-73.

PMID: 38934846 PMC: 11648731. DOI: 10.1093/ajhp/zxae177.


Barriers and Facilitators to the Outpatient Management of Low-risk Pulmonary Embolism From the Emergency Department.

Westafer L, Jessen E, Zampi M, Boccio E, Casey S, Lindenauer P Ann Emerg Med. 2023; 82(3):381-393.

PMID: 37596016 PMC: 10440853. DOI: 10.1016/j.annemergmed.2023.02.021.


Advanced practice provider-led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilization.

Frank C, Kasthuri R, Key N, Mooberry M, Wilson S, Moll S Res Pract Thromb Haemost. 2023; 7(4):100198.

PMID: 37416053 PMC: 10320239. DOI: 10.1016/j.rpth.2023.100198.


References
1.
Vazquez S, Freeman A, Vanwoerkom R, Rondina M . Contemporary issues in the prevention and management of postthrombotic syndrome. Ann Pharmacother. 2009; 43(11):1824-35. PMC: 3245967. DOI: 10.1345/aph.1M185. View

2.
Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, Gallus A . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. DOI: 10.1056/NEJMoa1007903. View

3.
Witt D, Sadler M, Shanahan R, Mazzoli G, Tillman D . Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005; 127(5):1515-22. DOI: 10.1378/chest.127.5.1515. View

4.
Locke C, Ravnan S, Patel R, Uchizono J . Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy. 2005; 25(5):685-9. DOI: 10.1592/phco.25.5.685.63582. View

5.
Dib J, Mohammed K, Momattin H, Alshehri A . Implementation of pharmacist-managed anticoagulation clinic in a saudi arabian health center. Hosp Pharm. 2014; 49(3):260-8. PMC: 3971112. DOI: 10.1310/hpj4903-260. View